secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0001104659-25-025828
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cognition Therapeutics reports 2024 net loss of $34M; highlights positive Phase 2 data for zervimesine
--------------------------------------------------------------------------------

- Cash and equivalents $25.0M at Dec 31 2024; $50.0M in NIA grant funds remaining.
- Net loss $34.0M ($0.86 per share) vs $25.8M ($0.86) in 2023; R&D expense $41.7M.
- Phase 2 SHIMMER DLB study: up to 91% slowing vs placebo across behavior, cognition, function, movement.
- Phase 2 SHINE Alzheimer's subgroup with lower p-tau217 showed near-total preservation of cognition.
- Plans to request end-of-Phase 2 FDA meetings in Q2 2025 for DLB and Alzheimer's; cash runway into Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465925025828/0001104659-25-025828-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465925025828/tm259712d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-025828

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer